Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
577.00    -21.00 (-3.51%)
Bid:
575.00
Ask:
577.00
Spread: 2.00 (0.348%)
Market Cap: £502.71m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Joint Venture

13 Jan 2020 08:46

RNS Number : 5673Z
Victrex PLC
13 January 2020
 

 

13 January 2020

Victrex plc

Investment to create a joint-venture for PEEK manufacture in China

Development of PEEK polymer capacity in China sets the stage for further regional growth opportunities and further differentiates Victrex's range of PEEK & PAEK grades

Victrex plc today announces the creation of a joint-venture between its subsidiary, Victrex Hong Kong Limited, and Yingkou Xingfu Chemical Company Limited, to build and operate a new PEEK polymer manufacturing facility in Liaoning, China, subject to certain performance conditions, including finalising land purchase and permit applications. Victrex, which will be the majority partner and lead the joint-venture, will benefit by further differentiating and complementing its portfolio of PEEK and PAEK grades, in anticipation of a range of significant long-term growth opportunities across several end markets in China, as well as aligning with China's 'Made in China 2025' initiative, where specifying domestically produced PEEK in certain applications is expected to gain momentum.

Victrex already has an established relationship with its joint-venture partner through its monomer supply chain, with Yingkou Xingfu having significant experience of developing and operating chemical facilities in China which meet international quality, process and environmental standards.

Today's announcement builds on Victrex's recent appointment of a General Manager for China and an increased commercial presence, as well as its strong technical service offering to customers, which includes its existing Technical Centre in Shanghai. The investment sets the stage for Victrex to serve some of its regional customers from a local facility and in a more diverse way. Victrex will also oversee the management of process know-how and intellectual property during development of the polymerisation process.

Victrex's share of the overall investment, the majority of which comprises capital investment during construction, is expected to total £32m funded in cash, with approximately £28m of capital expenditure and £4m of start-up costs, with commissioning of the facility anticipated in early 2022. The new plant will eventually be capable of producing up to 1,500 tonnes* per annum. Establishing a new PEEK polymer plant in China is in line with Victrex's record of investing in capacity ahead of demand, with an expectation that future capacity increases will be more gradual, rather than larger multi-year investments.

Jakob Sigurdsson, Chief Executive of Victrex, said: "This investment is in line with our record of not only investing ahead of demand, but in complementing and further differentiating our range of PEEK and PAEK grades, as well as setting the stage for specific geographic growth, whereby we can capitalise on the significant opportunities in China and the Asia Pacific region by having a competitive manufacturing presence there.

"Alongside the Made in China 2025 initiative, some of our increasingly diverse application areas mean our customers require a quality and differentiated PEEK offering. Whilst we already manufacture a range of PEEK and PAEK grades, this will enhance our portfolio, making us even better positioned in a region where we have seen strong growth in recent years and continue to see attractive opportunities, aligned to our know-how and strong technical and application development capabilities.

"Overall, we believe this is a good entry point to a China manufacturing operation, working with an established partner and offering an attractive returns profile."

The joint-venture will establish Victrex Hong Kong Limited as the majority partner with a 75% share, with leadership being assumed by Victrex once the facility is operational. The investment follows on from Victrex commencing a debottlenecking project at its main Hillhouse UK facilities in FY 2020, which will add up to 1,000 tonnes per annum of nameplate capacity when completed.

This announcement is a class 2 transaction made in requirement with the UK Listing Rules.

 

Notes

1/ *1,500 tonnes is based on anticipated annual nameplate capacity

2/ The gross asset value of the joint-venture is approximately £29.5m

3/ No profits are attributable to the assets of the joint-venture and formation of the joint-venture is not anticipated to materially affect expectations for the Group prior to operational completion

4/ Victrex will hold three of the four Board seats as part of the joint-venture, with Richard Armitage, Victrex Chief Financial Officer, chairing the joint-venture

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications

+44 (0) 1253 898121

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications which contain our materials - from smartphones, aeroplanes and cars to oil and gas operations and medical devices. With over 40 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com or follow us on LinkedIn and Twitter @victrexir

 

About Yingkou Xingfu:

Yingkou Xingfu is a well-established manufacturer of Speciality Chemicals in China and has been a valued partner to Victrex for nearly a decade in its monomer supply chain. They bring monomer manufacturing capability as well as a proven track record of building high quality chemical plants that meet international quality, process and environmental standards.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
JVEFIFSTLEIVLII
Date   Source Headline
31st Mar 20102:22 pmRNSTotal Voting Rights
30th Mar 201010:28 amRNSHolding(s) in Company
29th Mar 20102:13 pmRNSHolding(s) in Company
29th Mar 20102:09 pmRNSDirector/PDMR Shareholding
29th Mar 20102:05 pmRNSHolding(s) in Company
22nd Mar 20103:14 pmRNSHolding(s) in Company
17th Mar 20103:36 pmRNSDirector/PDMR Shareholding
12th Mar 20102:43 pmRNSDirector/PDMR Shareholding
10th Mar 20104:11 pmRNSDirector/PDMR Shareholding
9th Mar 20102:55 pmRNSDirector/PDMR Shareholding
5th Mar 20102:08 pmRNSHolding(s) in Company
3rd Mar 20102:35 pmRNSDirector/PDMR Shareholding
26th Feb 201011:22 amRNSTotal Voting Rights
24th Feb 20101:39 pmRNSDirector/PDMR Shareholding
23rd Feb 201011:43 amRNSDirector/PDMR Shareholding
18th Feb 201012:28 pmRNSDirector/PDMR Shareholding
17th Feb 20103:15 pmRNSDirector/PDMR Shareholding
10th Feb 201012:18 pmRNSResult of AGM
9th Feb 20107:00 amRNSAGM and Interim Management Statement
8th Feb 201011:47 amRNSHolding(s) in Company
1st Feb 20101:50 pmRNSTotal Voting Rights
25th Jan 20103:36 pmRNSHolding(s) in Company
19th Jan 20104:09 pmRNSDirector/PDMR Shareholding
15th Jan 201011:21 amRNSDirector/PDMR Shareholding
7th Jan 201010:53 amRNSAnnual Information Update
6th Jan 201012:15 pmRNSTotal Voting Rights
18th Dec 20099:11 amRNSAnnual Financial Report
17th Dec 20093:38 pmRNSDirector/PDMR Shareholding
16th Dec 20094:56 pmRNSDirector/PDMR Shareholding
11th Dec 200911:22 amRNSHolding(s) in Company
8th Dec 20097:00 amRNSBoard and management changes
8th Dec 20097:00 amRNSFinal Results
4th Dec 20091:38 pmRNSHolding(s) in Company
1st Dec 20091:42 pmRNSBlocklisting Interim Review
30th Nov 20094:08 pmRNSTotal Voting Rights
17th Nov 20093:07 pmRNSDirector/PDMR Shareholding
30th Oct 20092:22 pmRNSTotal Voting Rights
20th Oct 200912:51 pmRNSDirector/PDMR Shareholding
8th Oct 20097:00 amRNSAnnual Trading Update
30th Sep 20092:53 pmRNSTotal Voting Rights
23rd Sep 20097:00 amRNSBoard Change
18th Sep 20091:58 pmRNSDirector/PDMR Shareholding
4th Sep 20092:15 pmRNSDirector/PDMR Shareholding
28th Aug 20092:13 pmRNSTotal Voting Rights
19th Aug 200910:49 amRNSDirector/PDMR Shareholding
6th Aug 20097:00 amRNSInterim Management Statement
31st Jul 200912:06 pmRNSTotal Voting Rights
24th Jul 20091:13 pmRNSDirector/PDMR Shareholding
17th Jul 20092:24 pmRNSDirector/PDMR Shareholding
30th Jun 20093:38 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.